Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma | OncLive

Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma

May 4, 2016

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma. In the study, patients enrolled in the trial were stratified using the signature.

The HOVON-87/NMSG-18 study investigated patients who received induction therapy with melphalan, prednisone and thalidomide, followed by thalidomide maintenance therapy, compared with those who received melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy.

The EMC92/SKY92 signature was used in this study to identify patients with myeloma who are at high risk for poor prognosis and have a minimal progression-free survival rate, de Best explains. The EMC92/SKY92 signature was demonstrated to be a useful prognostic marker in the elderly population, she adds.


x